When was Akero Therapeutics founded?

Akero Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Akero Therapeutics located?

Akero Therapeutics is headquartered in San Francisco, United States. It is registered at South San Francisco, California.

Who is the current CEO of Akero Therapeutics?

Jonathan Young of Akero Therapeutics.

How many employees does Akero Therapeutics have?

As of Sep 30, 2026, the latest employee count at Akero Therapeutics is 74.

Is Akero Therapeutics a funded company?

Akero Therapeutics is a funded company, having raised a total of $135M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 22, 2018.

How much is Akero Therapeutics worth?

The last known valuation of Akero Therapeutics was $***** as of Oct 09, 2025.

When was the latest funding round of Akero Therapeutics?

Akero Therapeutics' latest funding was a $***** Post IPO round on Jun 16, 2022, with participation from 1 investor.

Where does Akero Therapeutics rank among its competitors?

Akero Therapeutics ranks 7th amongst 131 active competitors, of which 43 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Drug Farm, which secured $55M in Jul, 2026.

Who are the top competitors of Akero Therapeutics?

Akero Therapeutics' top competitors include Nimbus Therapeutics, Madrigal Pharmaceuticals and Mammoth. Among them, Drug Farm secured the most recent funding round in July, 2026.

Akero Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Akero Therapeutics is an acquired company based in San Francisco (United States), founded in 2017 by Tim Rolph and Jonathan Young. It operates as a Developer of small molecule therapeutics for metabolic disorders. Akero Therapeutics has raised $135M in funding from investors like Atlas Venture, Apple Tree Partners and Janus Henderson Investors, with last known valuation of $*****. The company has 131 active competitors, including 43 funded and 37 that have exited. Its top competitors include companies like Nimbus Therapeutics, Madrigal Pharmaceuticals and Mammoth.

Company Details

Developer of small molecule therapeutics for metabolic disorders. The company's lead product Efruxifermin that acts as an agonist of fibroblast growth factor 21 (FGF21) for the treatment of non-alcoholic steatohepatitis. It also offers products for fibrosis and liver diseases.

Website: akerotx.com
Social
Phone Number: +1 **********
Registered Address: South San Francisco, California

Key Metrics

Founded Year

2017

Location

San Francisco, United States

Stage

Acquired

Total Funding

$135M in 4 rounds

Latest Funding Round

Post IPO, Jun 16, 2022, $*****

Last Known Valuation

$***** as on Oct 09, 2025

Investors

Atlas Venture & 13 more

Ranked

7^th among 131 active competitors

Employee Count

74 as on Sep 30, 2026

Similar Companies

Nimbus Therapeutics & 84 more

Exit Details

Acquired by New Nordic (Oct 09, 2025)

View Akero Therapeutics' full profile

Akero Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
AKERO THERAPEUTICS, INC. CIN: 815266573 , United States, Active		-	61 (As on Dec 31, 2024)	-

Akero Therapeutics got acquired by New Nordic on Oct 09, 2025 at an acquisition amount of $*****.

Click here to take a look at Akero Therapeutics's acquisition in detail

Akero Therapeutics has raised a total funding of $135M over 4 rounds. Its first funding round was on Jun 22, 2018. Its latest funding round was a Post IPO round on Jun 16, 2022 for $*****. 1 investor participated in its latest round. Akero Therapeutics has 14 institutional investors.

Here is the list of recent funding rounds of Akero Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 16, 2022	5337052	Post IPO	3563246	9824931	5967479	6390133
Jul 10, 2020	5277931	Post IPO	4391237	6065199	3641773	2538515
Dec 12, 2018	5247902	Series B	1861931	3487991	Janus Henderson Investors	LifeSci Venture Partners & 9 more

Access funding benchmarks and valuations. Sign up today!

View details of Akero Therapeutics's funding rounds and investors

The founders of Akero Therapeutics are Tim Rolph and Jonathan Young.

Here are the details of Akero Therapeutics' key team members:

Tim Rolph: Co-Founder of Akero Therapeutics.
Contact Info: 1 email address
Jonathan Young: CEO of Akero Therapeutics.
Contact Info: 1 email address

View details of Akero Therapeutics's Founder profiles and Board Members

Akero Therapeutics' employee count trend

Akero Therapeutics has 74 employees as of Sep 26. Here is Akero Therapeutics's employee count trend over the years:

Employee count trend for Akero Therapeutics

Uncover Akero Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Akero Therapeutics include Nimbus Therapeutics, Madrigal Pharmaceuticals and Mammoth. Here is the list of Top 10 competitors of Akero Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
2nd	Madrigal Pharmaceuticals 2011, Conshohocken (United States), Acquired	Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis	$38.4M	HarbourVest Partners, Avoro Capital & 3 others	66/100
3rd	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Decheng Capital & 34 others	65/100
4th	Drug Farm 2015, Shanghai (China), Series D	Developer of a novel treatment for metabolic diseases	$138M	Shanghai Pudong Leading Area Investment Center, Zhejiang Private Enterprise United Investment ... & 13 others	64/100
5th	Intercept Pharmaceuticals 2002, New York City (United States), Acquired	Developer of therapeutics to treat progressive non-viral liver diseases	$121M	Orbimed, JAFCO Group & 7 others	63/100
6th	Mirum Pharmaceuticals 2018, Menlo Park (United States), Public	Developer of small molecule based therapeutics to treat rare diseases	$120M	New Enterprise Associates, Oberland Capital ... & 9 others	61/100
7th	Akero Therapeutics 2017, San Francisco (United States), Acquired	Developer of small molecule therapeutics for metabolic disorders	$135M	BVF Partners, Atlas Venture & 12 others	61/100
8th	Altimmune 1997, Gaithersburg (United States), Acquired	Developer of vaccines for infectious disease including influenza, hepatitis B and solid tumors	$58M	Gershon Capital, Fidelis Capital & 15 others	60/100
9th	Enyo Pharma 2014, Lyon (France), Series C	Developer of therapeutics for diseases with impaired kidney function	$120M	Orbimed, Morningside & 9 others	60/100
10th	Terns Pharmaceutical 2017, San Mateo (United States), Acquired	Developer of therapies for treating liver disease and cancer	$208M	Lilly Asia Ventures, Deerfield & 6 others	60/100